Komo

AI drug discovery

What is Isomorphic Labs?

Alphabet-backed AI drug-design company commercializing AlphaFold-era biology models.

Category
AI drug discovery
Headquarters
London, England
Founded
2021
Employees
300+ reported across London, Lausanne, and Cambridge
Total funding
$600 million external funding disclosed
Status
Alphabet subsidiary

What is Isomorphic Labs?

Isomorphic Labs is a ai drug discovery company headquartered in London, England.

Isomorphic Labs applies AI to drug design, using AlphaFold-related advances and its own drug design engine to discover small-molecule therapeutics. The company has announced collaborations with Novartis and Eli Lilly and is backed by Alphabet, GV, and Thrive Capital.

The company was founded in 2021 and remains alphabet subsidiary. Its public profile is strongest around Drug Design Engine and AlphaFold-related modeling, while detailed revenue figures are not publicly disclosed.

As of June 2026, the safest public read is that Isomorphic Labs is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.

Sources:Isomorphic Labs websiteIsomorphic Labs funding announcement

What does Isomorphic Labs offer?

Isomorphic Labs's public product set centers on Drug Design Engine, AlphaFold-related modeling, Small-molecule programs.

  • Drug Design Engine· AI biology
  • AlphaFold-related modeling· Protein structure
  • Small-molecule programs· Drug discovery
  • Pharma collaborations· Partnerships

Sources:Isomorphic Labs website

How does Isomorphic Labs make money?

Drug-discovery partnerships, internal pipeline value creation, and milestone-based pharma collaborations; no software pricing is public.

Drug-discovery partnerships, internal pipeline value creation, and milestone-based pharma collaborations; no software pricing is public. No public software pricing; business model is pharma collaboration and pipeline economics.

Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Isomorphic Labs does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.

The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.

Sources:Isomorphic Labs websiteWikipedia Isomorphic Labs

Who leads Isomorphic Labs?

Isomorphic Labs is led by Demis Hassabis, Founder and CEO.

  • Demis HassabisFounder and CEOFounder · since 2021DeepMind co-founder and Nobel laureate leading Isomorphic and Google DeepMind.
  • Max JaderbergPresident / AI leaderExecutiveFormer DeepMind researcher leading AI strategy.
  • Miles CongreveChief Scientific OfficerExecutiveDrug-discovery scientist leading therapeutic science.
  • Sergei YakneenChief Technology OfficerExecutiveTechnology leader for AI drug-design systems.

Sources:Isomorphic Labs websiteIsomorphic Labs funding announcement

Who are Isomorphic Labs's decision-makers?

How do you contact Isomorphic Labs's leadership?

Public contact route; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.

Email formatPublic contact route; no verified personal email pattern found

    Sources:Isomorphic Labs website

    How much funding has Isomorphic Labs raised?

    Isomorphic Labs has $600 million external funding disclosed and is alphabet subsidiary.

    2021: Alphabet formation — Undisclosed internal funding, led/backed by Alphabet. 2025-03: First external round — $600 million, led/backed by Thrive Capital with GV and Alphabet (Valuation undisclosed).

    The latest public valuation/status marker is Undisclosed; Alphabet subsidiary. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.

    Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.

    Sources:Isomorphic Labs funding announcementWikipedia Isomorphic Labs

    How much has Isomorphic Labs raised?

    How did Isomorphic Labs get here?

    Isomorphic Labs's timeline runs from its 2021 founding through major financing and product milestones.

    1. 2021Founded by AlphabetIsomorphic Labs launched as an Alphabet company led by Demis Hassabis.
    2. 2024Novartis and Lilly partnershipsThe company announced AI drug-discovery collaborations with major pharma companies.
    3. 2025First external roundIsomorphic raised $600 million led by Thrive Capital.
    4. 2026Drug Design Engine announcedThe company described its next-generation AI drug design engine beyond AlphaFold.
    5. 2026Multi-site growthPublic profiles describe operations in London, Lausanne, and Cambridge.

    Sources:Isomorphic Labs websiteIsomorphic Labs funding announcement

    Who are Isomorphic Labs's competitors?

    Isomorphic Labs competes with specialized startups and larger platform companies in ai drug discovery.

    • RecursionAI-enabled drug discovery with clinical-stage pipeline.
    • Insilico MedicineAI drug discovery and generative chemistry platform.
    • Generate:BiomedicinesGenerative biology platform for protein therapeutics.
    • Iambic TherapeuticsAI-driven small-molecule drug discovery.

    Sources:Isomorphic Labs websiteWikipedia Isomorphic Labs

    Isomorphic Labs — frequently asked questions

    Agent CTA Background

    Revenue work. On autopilot.

    Start Free TrialBuilt for revenue teams who care about quality.